How Vivek Ramaswamy Plans To Speed Drug Research And Cure Alzheimer’s Disease

Ramaswamy targets promising drugs from big pharma which–because of strategy, market tastes, or politics–have stalled in clinical trials. His company Roivant buys these half-developed drugs, with the aim to rescue them drugs from the regulatory bottleneck, pushing them through the FDA.

from Forbes – Tech http://ift.tt/2lAlKpV
via IFTTT